• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form DEFR14A filed by Agape ATP Corporation

    1/28/26 4:00:16 PM ET
    $ATPC
    Medical/Nursing Services
    Health Care
    Get the next $ATPC alert in real time by email
    DEFR14A 1 formdefr14a.htm DEFR14A

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D. C. 20549

     

    AMENDMENT NO. 1

    TO

    SCHEDULE 14A INFORMATION

    Proxy Statement Pursuant to Section 14(a) of the

    Securities Exchange Act of 1934

     

    Filed by the Registrant ☒   Filed by a party other than the Registrant ☐

     

    Check the appropriate box:

     

    ☐ Preliminary Proxy Statement
       
    ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))
       
    ☒ Definitive Proxy Statement
       
    ☐ Definitive Additional Materials
       
    ☐ Soliciting Material under §240.14a-12

     

    AGAPE ATP CORPORATION

    (Name of Registrant as Specified in Its Charter)

     

     

    (Name of Person(s) Filing Proxy Statement, if other than the Registrant)

     

    Payment of Filing Fee (Check all boxes that apply):

     

    ☒ No fee required
       
    ☐ Fee paid previously with preliminary materials
       
    ☐ Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11

     

     

     

       

     

     

    EXPLANATORY NOTE

     

    This Amendment No. 1 to Schedule 14A (this “Amendment”) amends our definitive proxy statement (the “Proxy Statement”) filed with the Securities and Exchange Commission on January 9, 2026 regarding the Annual Meeting of the Stockholders (the “Annual Meeting”) of Agape ATP Corporation, a Nevada corporation (the “Company”), which will be held at 10:00 p.m., Malaysia Time (10:00 a.m., Eastern Time) on January 30, 2026.

     

    From and after the date of this Amendment, all references to the “Proxy Statement” are to the Proxy Statement as amended hereby. The Proxy Statement contains important information, and this Amendment should be read in conjunction with the Proxy Statement.

     

    If you have already voted and would like to change or revoke your vote on any proposal, please refer to the disclosure in the Proxy Statement for instructions on how to do so.

     

     

     

     

    AMENDMENT TO PROXY STATEMENT

     

    The purpose of this Amendment is to amend certain paragraphs in the definitive proxy statement on Schedule 14A filed by Agape ATP Corporation.

     

    What are Abstentions and Broker Non-Votes?

     

    The section “What are Abstentions and Broker Non-Votes” appears on page 4. The section is amended and restated to read in its entirety as follows:

     

    All votes will be tabulated by the inspector of election appointed for the Annual Meeting, who will separately tabulate affirmative and negative votes, abstentions and broker non-votes. An abstention is the voluntary act of not voting by a Stockholder who is present at the Annual Meeting and entitled to vote. A broker “non-vote” occurs when a broker nominee holding shares for a beneficial owner does not vote on a particular proposal because the nominee does not have discretionary power for that particular item and has not received instructions from the beneficial owner. If you hold your shares in “street name” through a broker or other nominee, your broker or nominee may not be permitted to exercise voting discretion with respect to some of the matters to be acted upon at the Annual Meeting. If you do not give your broker or nominee specific instructions regarding such matters, your proxy will be deemed a “broker non-vote.”

     

    The question of whether your broker or nominee may be permitted to exercise voting discretion with respect to a particular matter depends on whether the particular proposal is deemed to be a “routine” matter and how your broker or nominee exercises any discretion they may have in the voting of the shares that you beneficially own. Brokers and nominees can use their discretion to vote “uninstructed” shares with respect to matters that are considered to be “routine,” but not with respect to “non-routine” matters. Under the rules and interpretations of the Nasdaq, “non-routine” matters are matters that may substantially affect the rights or privileges of Stockholder, such as mergers, Stockholder proposals, elections of directors (even if not contested), executive compensation (including any advisory Stockholder votes on executive compensation and on the frequency of Stockholder votes on executive compensation), and certain corporate governance proposals, even if management-supported.

     

    For any proposal that is considered a “routine” matter, your broker or nominee may vote your shares in its discretion either for or against the proposal even in the absence of your instruction. For any proposal that is considered a “non-routine” matter for which you do not give your broker instructions, the shares will be treated as broker non-votes. “Broker non-votes” occur when a beneficial owner of shares held in street name does not give instructions to the broker or nominee holding the shares as to how to vote on matters deemed “non-routine.” Broker non-votes will not be considered to be shares “entitled to vote” on any “non-routine” matter and therefore will not be counted as having been voted on the applicable proposal. Therefore, if you are a beneficial owner and want to ensure that shares you beneficially own are voted in favor or against any or all of the proposals in this proxy statement, the only way you can do so is to give your broker or nominee specific instructions as to how the shares are to be voted.

     

       

     

     

    Abstentions and broker non-votes are not counted as votes cast on an item and therefore will not affect the outcome of any proposal presented in this proxy statement. Abstention and broker non-votes, if any, will be counted for purposes of determining whether there is a quorum present at the Annual Meeting.

     

    Accordingly, we encourage you to provide voting instructions to your broker, whether or not you plan to attend the Annual Meeting.

     

    PROPOSAL 5. TO APPROVE AN AMENDMENT TO THE COMPANY’S ARTICLES OF INCORPORATION TO INCREASE THE NUMBER OF AUTHORIZED SHARES OF COMMON STOCK FROM 500,000,000 TO 30,000,000,000. (ITEM 5 ON THE PROXY CARD).

     

    The paragraph “Required Vote and Recommendation” appears on page 15 under the section: PROPOSAL 5. TO APPROVE AN AMENDMENT TO THE COMPANY’S ARTICLES OF INCORPORATION TO INCREASE THE NUMBER OF AUTHORIZED SHARES OF COMMON STOCK FROM 500,000,000 TO 30,000,000,000. (ITEM 5 ON THE PROXY CARD). The paragraph of such section is amended and restated to read in its entirety as follows:

     

    The affirmative “FOR” vote of holders of a majority of the voting shares of the Company is required to approve this proposal. Abstentions and broker non-votes, if any, will count as “NO” votes for this proposal.

     

    PROPOSAL 6. TO CONDUCT ANY OTHER BUSINESS AS MAY PROPERLY COME BEFORE THE MEETING OR ANY ADJOURNMENT THEREOF. (ITEM 6 ON THE PROXY CARD)

     

    The paragraph “Required Vote of Stockholders” appears on page 16 under the section: PROPOSAL 6. TO CONDUCT ANY OTHER BUSINESS AS MAY PROPERLY COME BEFORE THE MEETING OR ANY ADJOURNMENT THEREOF. (ITEM 6 ON THE PROXY CARD). The paragraph of such section is amended and restated to read in its entirety as follows:

     

    The approval of Proposal 6 requires that holders of a majority of the shares present in person or by proxy at the Annual Meeting and entitled to vote thereon vote “FOR” Proposal 6. Abstentions are considered votes present and entitled to vote on this proposal, and thus, will have the same effect as a vote “against” the proposal. Because Proposal 6 is considered a “routine” matter under applicable stock exchange rules, we do not expect to receive any broker non-votes on this proposal.

     

       

     

     

    Get the next $ATPC alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ATPC

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $ATPC
    SEC Filings

    View All

    SEC Form S-3 filed by Agape ATP Corporation

    S-3 - Agape ATP Corp (0001713210) (Filer)

    2/6/26 1:28:39 PM ET
    $ATPC
    Medical/Nursing Services
    Health Care

    Agape ATP Corporation filed SEC Form 8-K: Material Modification to Rights of Security Holders, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Agape ATP Corp (0001713210) (Filer)

    2/6/26 11:00:50 AM ET
    $ATPC
    Medical/Nursing Services
    Health Care

    Agape ATP Corporation filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Agape ATP Corp (0001713210) (Filer)

    2/5/26 9:00:21 AM ET
    $ATPC
    Medical/Nursing Services
    Health Care

    $ATPC
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    ATPC Expands Global Market Footprint to Spearhead Medical Innovation with MoUs in Indonesia

    Agreements to drive clinical research, enhance product safety, and combat respiratory diseases KUALA LUMPUR, MALAYSIA / ACCESSWIRE / November 29, 2024 / NASDAQ-listed AGAPE ATP Corporation ("ATPC"), today announced the signing of three Memorandums of Understanding ("MOUs") with prominent healthcare institutions in Indonesia. This initiative aims to advance medical research, introduce innovative treatment strategies and strengthen training programs to address respiratory diseases such as tuberculosis (TB) and chronic obstructive pulmonary disease (COPD). The signing marks a key milestone in ATPC's strategic expansion plans in Indonesia and Southeast Asia.(L-R): Dr. Fernando Cortizo, ED, Prof.

    11/29/24 9:00:00 AM ET
    $ATPC
    Medical/Nursing Services
    Health Care

    Agape ATP Corporation - Synergising Innovation Across Business Pillars to Make the World a Better Place

    ATPC Unveils Its Multifaceted Business Pillars to Drive Global Wellness and Sustainability KUALA LUMPUR, MALAYSIA / ACCESSWIRE / October 10, 2024 / NASDAQ-listed AGAPE ATP Corporation ("ATPC"), is proud to present its multifaceted business pillars, each driven by a shared vision to make the world a better place. With a strong commitment to sustainability, health, and enhancing quality of life, ATPC has strategically developed six (6) core pillars that work in synergy to address the world's most pressing challenges, from energy conservation to advanced medical care.ATPC Green Energy ("AGE") spearheads ATPC's efforts in the energy sector, with initiatives aiming to provide sustainable energy s

    10/10/24 9:20:00 AM ET
    $ATPC
    Medical/Nursing Services
    Health Care

    ATPC and FORMEDIC Technologies Announce Strategic Collaboration to Launch LEGA, a Revolutionary Respiratory Care Device

    Innovative Collaboration Brings Advanced Respiratory Solutions to a Global Market KUALA LUMPUR, MALAYSIA / ACCESSWIRE / September 30, 2024 / NASDAQ-listed AGAPE ATP Corporation ("ATPC"), is proud to announce a strategic collaboration with FORMEDIC Technologies Sdn. Bhd. ("FORMEDIC Technologies") to introduce LEGA, an electronic chest percussion device for respiratory care. This partnership marks a major advancement in respiratory health, as the two companies combine their strengths to address the growing demand for advanced respiratory solutions.LEGA, FORMEDIC's flagship product, assists patients with chronic obstructive pulmonary diseases ("COPD"), pneumonia, bronchiectasis, and other lung-

    9/30/24 11:45:00 PM ET
    $ATPC
    Medical/Nursing Services
    Health Care

    $ATPC
    Leadership Updates

    Live Leadership Updates

    View All

    Agape ATP Corporation Announces US$1 Million Share Repurchase Plan

    KUALA LUMPUR, MALAYSIA / ACCESSWIRE / November 22, 2023 / AGAPE ATP Corporation (NASDAQ:ATPC) ("ATPC" or the "Company") announced that its board of directors has authorized a share repurchase plan under which the Company may repurchase up to US$1 million of its shares over the next 6 months. The board of directors have also approved the appointment of Network 1 Financial Securities as the broker to execute the repurchase on behalf of ATPC.The share repurchases may be made from time to time in the open market transactions, in privately negotiated transactions, in block trades and/or through other legally permissible means, depending on market conditions and in accordance with applicable secur

    11/22/23 9:00:00 AM ET
    $ATPC
    Medical/Nursing Services
    Health Care